ImmunoGen aims to conduct Phase I study of lymphoma drug

09/25/2011 | American City Business Journals

ImmunoGen submitted an application to the FDA seeking approval to launch a Phase I trial of IMGN529, a drug candidate for patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company said the drug contains an antibody that facilitates death of tumor cells by delivering anti-cancer agent DM1 directly to B cells.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC